Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Fish and Richardson
Boehringer Ingelheim
Merck
Medtronic
US Army
Daiichi Sankyo
Argus Health
Fuji

Generated: February 17, 2019

DrugPatentWatch Database Preview

Pazopanib hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for pazopanib hydrochloride and what is the scope of pazopanib hydrochloride patent protection?

Pazopanib hydrochloride is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pazopanib hydrochloride has forty patent family members in twenty-five countries.

There are five drug master file entries for pazopanib hydrochloride. One supplier is listed for this compound.

Summary for pazopanib hydrochloride
Synonyms for pazopanib hydrochloride
33Y9ANM545
5-((4-((2,3-DIMETHYL-2H-INDAZOL-6-YL)(METHYL)AMINO)PYRIMIDIN-2-YL)AMINO)-2-METHYLBENZENESULFONAMIDE HYDROCHLORIDE
5-((4-((2,3-Dimethyl-2H-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide monohydrochloride
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide Hydrochloride
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride
5-({4-[(2,3-dimethylindazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride
5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride
5-[[4-[(2,3-dimethyl-6-indazolyl)-methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride
5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide hydrochloride
635702-64-6
786034 HYDROCHLORIDE
A834417
AC-24726
AK163181
AKOS015958593
AM20090655
AN-16933
Armala
ARMALA HYDROCHLORIDE
AX8294838
BCP9001052
Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, monohydrochloride
Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1)
C21H23N7O2S.HCl
CHEBI:71217
CHEMBL1201733
CS-0126
D05380
DTXSID70212956
EX-A956
FT-0687642
GSK-786034
GW 786034
GW 786034 HYDROCHLORIDE
GW-786034B
GW786034B
GW786034GW786034
HY-12009
KB-79770
KS-000003E0
KS-1458
MFCD12546138
MLS004774147
MolPort-009-679-403
MQHIQUBXFFAOMK-UHFFFAOYSA-N
NSC-737754
NSC737754
Patorma
Pazopanib (Hydrochloride)
pazopanib HCl
Pazopanib HCl (GW786034 )
Pazopanib HCl (GW786034 HCl)
Pazopanib hydrochloride (JAN/USAN)
Pazopanib hydrochloride [USAN:JAN]
pazopanib monohydrochloride
PB31655
S1035
SC-90768
SCHEMBL159487
SMR003500790
ST24048877
SYN1058A
UNII-33Y9ANM545
Votrient
Votrient (TN)
VOTRIENT HYDROCHLORIDE
W-5532
X3177

US Patents and Regulatory Information for pazopanib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for pazopanib hydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1343782/01 Switzerland ➤ Sign Up FORMER OWNER: GLAXOSMITHKLINE LLC, US
C0037 France ➤ Sign Up PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614
C025/2010 Ireland ➤ Sign Up SPC025/2010: 20110401, EXPIRES: 20250613
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Cipla
Accenture
US Army
Julphar
Chinese Patent Office
McKinsey
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.